Tag: Cancer: Bladder
Trends in Genitourinary Cancers Examined in the United States
Among non-Hispanic Whites, highest incidence rates seen in Northeast for bladder cancer, Appalachia for kidney cancer
FDA Approves Gene Therapy for Tough-to-Treat Bladder Cancer
About 57,000 men and 18,000 women are diagnosed with bladder cancer annually
Smoking Duration, Intensity Tied to Bladder Cancer Recurrence
Pipes, cigars, e-cigarettes, or marijuana not tied to recurrence risk
Nab-Paclitaxel, Pembrolizumab Combo Active in Advanced Urothelial Cancer
Overall response rate 50 percent among 36 patients with platinum-refractory or cisplatin-ineligible advanced urothelial cancer
Patients Favor Single-Port Robotic System for Uro-Oncology Surgery
Patients in the single-port versus multiport system group reported better cosmetic appearance, higher satisfaction with cosmetic appearance of surgical scar
Gemcitabine/Docetaxel Treats Nonmuscle-Invasive Bladder Cancer
Authors say Gem/Doce warrants further study for the treatment of BCG-naive high-risk non-muscle-invasive bladder cancer
Risk Stratification Examined for High-Grade Ta Bladder Tumors
For patients treated with adequate BCG, risk for BCG unresponsiveness, progression similar for all high-grade Ta tumors
AUA: Outcomes of Robotic, Open Cystectomy Compared in Bladder Cancer
Number of days alive and out of hospital within first 90 days greater for robot-assisted surgery, but clinical significance of findings unclear
AUA: Immunotherapy Aids Survival in Muscle-Invasive Bladder Cancer
Patients receiving nivolumab had an approximately 30 percent lower likelihood of developing cancer recurrence versus placebo
AUA: Pandemic Disruptions Impacted One in Four Prostate, Bladder Cancer Patients
Changes, delays, and cancellation of cancer treatment and ancillary care reported
